Figure Legends
Figure 1: Effect of mepolizumab on blood and sinonasal tissue eosinophil levels. Blood samples and tissue biopsies were collected during baseline, 4, 8, 16, 24 week visits, prior to Mepolizumab administration. Blood eosinophil levels and tissue eosinophil counts per 0.1mm2 were evaluated and represented as mean values±standard deviation of 20 eCRS participants.
Figure 2: Effect of mepolizumab on sinonasal tissue eosinophil levels. Representative microscopic images of medium power view of haematoxylin and eosin (H&E) (A, B) of a single patient at baseline (A) and end of treatment (B).
Figure 3: Cytokine response in sinonasal tissue following treatment with mepolizumab. Type-2 (A-D), type-1 (E, F) and regulatory (G) cytokine levels in homogenised sinonasal tissue biopsies were measured by immunoassay at baseline and end of treatment of 20 patients with eosinophilic chronic rhinosinusitis patients treated with mepolizumab. Data was statistically analysed by paired T tests. Data is presented as mean values +/- SD and analysed by paired T test. ns = P > 0.05; * = P ≤ 0.05; ** = P ≤ 0.01; *** = P ≤ 0.001.